evidoria

← Back to browse

Good practice Imported

Tech Park Basel — Life Sciences Startup Incubator

Switzerland · Basel · See the Switzerland profile · See the Basel profile

Evidence: Observational / pre–post Top 42% 71/100 · Ask Evidence Copilot about this practice

Basel's university-adjacent biotech incubator — 68 startups since 2011, 1,000+ jobs (620 on-site, 466 alumni), CHF 3 billion+ capital raised, 5 exits including a CHF 1 billion+ acquisition, per the 2024 BAK Economics/EvalueScience independent impact study.

68 startups
Startups supported since founding (2011-2024)
1,000+ jobs
Total jobs created (as of 2024)
CHF 3 billion+
Private capital raised across portfolio
5
Corporate exits
86 %
Portfolio companies holding patents or licences
CHF 587 million
Financing raised by tenants in 2021 alone (2021)
94 %
Occupancy rate (2023)
Tech Park Basel — Life Sciences Startup Incubator

Details

Maturity
Established
Promoter
Tech Park Basel AG
Period
2011–present
Region (NUTS)
CH03
Keywords
Life sciences, biotech, medtech, pharma spin-offs

Context

Tech Park Basel is a life-sciences startup incubator that has operated since 2011 in the city of Basel, co-located with the University of Basel and University Hospital Basel and within the orbit of Novartis and Roche's global R&D headquarters, across 6,700 square metres of purpose-built laboratory and office space.

Results

A 2024 independent impact assessment commissioned by SwissParks and carried out by BAK Economics AG and EvalueScience AG surveyed 65 of the 68 startups the park has supported since founding, finding more than 1,000 jobs created (620 on-site plus 466 at alumni companies), over CHF 3 billion in private capital raised across the portfolio, five corporate exits including a CHF 1 billion-plus acquisition, and 86% of portfolio companies holding patents or licences.

Conclusions

The assessment credits the park's model of concentrating pharma-incumbent spin-outs alongside academic entrepreneurship in a single dense cluster with creating a self-reinforcing pipeline from laboratory to commercial exit, though the evaluation is a survey-based impact study rather than a comparison against a counterfactual.

Implementation
Indicative cost
High (€500k–€5M)
Time to results
Long (> 3 years)
Staffing & skills
Tech Park Basel AG operates the incubator as promoter and site operator., On-site employment across the park grew from 31 to 365 staff over its first decade.

Conditions for success

  • Co-location with the University of Basel and University Hospital Basel.
  • Proximity to Novartis and Roche global R&D headquarters.
  • Purpose-built 6,700 m2 biotech laboratory and office space.
  • A pipeline combining university spin-offs (30%) with pharma-incumbent spin-outs (15% from Novartis/Roche).

Commonly funded by

Own resources / municipal budget

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Replication kit

Reusable artefacts from this practice — as published by their sources.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful